Pharmaceutics I: Intermolecular Forces, States of Matter, Drug Development, and Pharmacy History

Comprehensive vocabulary flashcards covering intermolecular forces, states of matter, the drug development and approval process, current Good Manufacturing Practices (cGMPs), and the history and legal framework of pharmacy.

Intermolecular Forces (IMFs)

Momentary (temporary) electrostatic attractions between molecules, diatomic free elements, and individual atoms caused by the temporary polarization of particles.

Intramolecular Forces

Stable chemical bonds (such as covalent and ionic bonds) that hold atoms together within a molecule, possessing significantly higher binding energies than intermolecular forces.

Cohesive Forces

Attractive intermolecular forces that occur between molecules of the same kind (like molecules).

Adhesive Forces

Attractive intermolecular forces that occur between different types of molecules (unlike molecules).

Repulsive Forces

Intermolecular forces that arise when atoms or molecules are brought so close together that their electron clouds interpenetrate, resulting in positive potential energy.

Potential Energy Diagram

A plot of potential energy versus intermolecular distance showing net attraction at negative potential energies, a minimum energy well representing optimal separation, and steep repulsion (positive potential energy) at interpenetrating distances.

Keesom Forces

Dipole-dipole attractive forces between polar molecules possessing permanent dipoles, in which opposite partial charges align with an interaction energy typically between $1\text{ to }7\,\text{kcal/mol}$.

Debye Forces

Dipole-induced dipole forces that occur when a permanent dipole on a polar molecule induces a temporary dipole in a nearby easily polarizable nonpolar molecule, having an interaction energy of $1\text{ to }3\,\text{kcal/mol}$.

London Dispersion Forces

Induced dipole-induced dipole attractive forces between nonpolar molecules resulting from internal electron fluctuations and synchronized temporary dipoles, having an interaction energy of $0.5\text{ to }1\,\text{kcal/mol}$.

Hydrogen Bond

A strong form of dipole-dipole attraction occurring between an electropositive hydrogen atom and a strongly electronegative atom (primarily $\text{O}$, $\text{N}$, or $\text{F}$), exhibiting binding energies between $2\text{ to }40\,\text{kcal/mol}$.

Ion-Dipole Forces

Electrostatic attractive forces between a charged ion (cation or anion) and a polar molecule, which account for the aqueous solubility of ionic crystalline compounds.

Surface Tension

The inward cohesive force experienced by molecules at a liquid surface pulling them toward the bulk, which contracts the surface and creates tension across the liquid-gas interface.

Equilibrium Vapor Pressure

The pressure exerted by a vapor in thermodynamic equilibrium with its liquid phase in a closed container at a fixed temperature, where the rate of vaporization equals the rate of condensation.

Clausius-Clapeyron Equation

A thermodynamic relationship that calculates the equilibrium vapor pressure of a liquid at different temperatures based on its molar heat of vaporization ($\Delta H_{vap}$).

Boiling Point

The temperature at which the equilibrium vapor pressure of a liquid equals the surrounding atmospheric pressure.

Boltzmann Distribution Law

A physical law describing the fraction of molecules that possess a specific kinetic energy (and corresponding phase state) at a given temperature.

Crystalline Solids

Solids characterized by long-range three-dimensional order composed of a crystal lattice built from repeating unit cells, possessing definite and sharp melting points.

Polymorphism

The ability of a chemical solid to crystallize into more than one distinct crystalline form, resulting in identical chemical structures but distinct physical properties such as melting point, solubility, and bioavailability.

Amorphous Solids

Noncrystalline solids lacking long-range molecular order or a regular crystal lattice, exhibiting no sharp melting point and displaying higher solubility and bioavailability compared to crystalline forms.

Glass Transition Temperature ($T_g$)

The characteristic temperature range below which an amorphous solid behaves as a brittle glass (glassy state) and above which it behaves as a flexible, rubbery material (rubbery state).

Polymeric Solids

Solids composed of repeating monomer units joined to form macromolecular polymers, which can exist in crystalline, amorphous, or mixed states depending on their thermal history.

Eutectic Mixture

A specific mixture of solid substances that liquefies at a lower temperature than the melting point of any individual component at a defined ratio.

Eutectic Point ($T_E$)

The lowest possible temperature at which a liquid phase can exist in equilibrium with solid phases in a multicomponent system.

Drug

An agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in humans or other animals.

New Drug (FDA Definition)

Any drug not recognized by the FDA as safe and effective, including new chemical entities, new combinations, changes in proportions, new formulations, new indications, or altered dosage forms/routes.

Preclinical Research

The initial discovery phase encompassing chemical synthesis, purification, analytical testing, and laboratory animal studies to evaluate pharmacology and toxicology prior to human testing.

Pharmacodynamics

The branch of pharmacology addressing the biochemical and physiological effects of a drug on the body and its mechanism of action (MOA).

Pharmacokinetics

The study of the disposition of a drug within the body over time, encompassing absorption, distribution, metabolism, and excretion (ADME).

Preformulation

The early stage of dosage form development focused on characterizing the physical, chemical, and mechanical properties of a drug molecule (such as particle size, crystal habit, solubility, and stability) to ensure a uniform, stable formulation.

Investigational New Drug (IND) Application

A formal submission to the FDA detailing preclinical pharmacology, toxicology, manufacturing data, and clinical protocols required to secure permission to begin clinical testing in humans.

Clinical Hold

An order issued by the FDA delaying the start of clinical trials or suspending ongoing clinical studies under an IND application until deficiencies are addressed.

Phase 1 Clinical Trials

Initial human trials evaluating safety, safe dosage ranges, side effects, and human pharmacokinetics, typically conducted in $20\text{ to }80$ healthy volunteers.

Phase 2 Clinical Trials

Controlled clinical studies in $100\text{ to }300$ patient volunteers with the target disease to assess preliminary clinical efficacy, acute side effects, and determine MED, MTD, and MTC.

Therapeutic Index ($TI$)

A quantitative measure of drug safety calculated as the median toxic dose divided by the median effective dose ($TI = \frac{TD_{50}}{ED_{50}}$), where a higher number denotes a safer drug.

Phase 3 Clinical Trials

Expanded pivotal controlled and uncontrolled studies in $1{,}000\text{ to }3{,}000$ patient volunteers designed to confirm therapeutic efficacy, monitor adverse effects from long-term use, and evaluate the overall risk-benefit balance.

New Drug Application (NDA)

A formal submission to the FDA requesting approval to market and commercialize a new pharmaceutical product, compiling all preclinical and clinical safety, efficacy, and manufacturing data.

Phase 4 Post-Marketing Surveillance

Ongoing monitoring of approved drugs in clinical practice to identify rare adverse effects, long-term safety profiles, and efficacy in specialized patient subpopulations.

Supplemental New Drug Application (sNDA)

An FDA application submitted to gain approval for significant changes to an already marketed drug, such as manufacturing site modifications, formulation changes, or new packaging standards.

Abbreviated New Drug Application (ANDA)

A streamlined FDA approval pathway for generic drug products that does not require preclinical and clinical safety and efficacy studies, requiring instead proof of bioequivalence to the reference listed drug.

Bioequivalence

The absence of a significant difference in the rate and extent of absorption of the active pharmaceutical ingredient into the systemic circulation between a generic and a brand-name drug under similar experimental conditions.

Current Good Manufacturing Practices (cGMPs)

Federal regulations (21 CFR Part 211) enforced by the FDA establishing requirements for the methods, facilities, and controls used in the manufacturing, processing, packaging, and holding of drug products to ensure quality, identity, and purity.

FDA Form 483

An inspectional notice issued by FDA investigators documenting observed conditions or practices that may indicate violations of cGMP requirements.

Standard Operating Procedures (SOPs)

Authorized stepwise written instructions describing the purpose, frequency, responsible personnel, procedure, and corrective steps for a specific manufacturing, testing, or maintenance task.

Papyrus Ebers

An ancient Egyptian pharmaceutical scroll dating to approximately $1500\,\text{BC}$, measuring 60 feet long by 1 foot wide, containing roughly 800 formulas and 700 distinct drugs.

Hippocrates

An ancient Greek physician ($460\text{--}377\,\text{BC}$) regarded as the 'Father of Medicine', credited with separating medicine from mysticism, introducing medical ethics, and coining 'pharmakon' as a purifying remedy used for good.

Dioscorides

A 1st-century AD Greek physician and botanist in the Roman army who wrote 'De Materia Medica', a landmark work identifying roughly 600 plants and 1,000 remedies that served as the primary medical/botanical reference for 1,700 years.

Galenic Pharmacy

The system of compounding medicines using mechanical methods from plant and natural materials, established by the Greek physician and surgeon Galen ($130\text{--}200\,\text{AD}$).

Avicenna

A prominent Persian intellectual (~$1000\,\text{AD}$) known as the 'Galen of Persia', whose medical and pharmaceutical texts served as authoritative references in Europe and Asia through the 17th century.

Edict of Salerno

A decree issued in 1240 AD by Emperor Frederick II separating pharmacy from medicine as an independent profession and requiring pharmacists to compound medicines reliably 'secundum artem' (according to the art).

Nuovo Receptario

The first official pharmacopoeia, published in Florence, Italy in 1498 through a collaboration between the Guild of Apothecaries and the Medical Society.

United States Pharmacopeia (USP)

The national compendium of drug standards established in 1820 by Dr. Lyman Spaulding to create uniform drug purity and potency specifications across the United States.

National Formulary (NF)

A drug compendium first published in 1888 by the American Pharmaceutical Association (APhA) as the National Formulary of Unofficial Preparations to include widely used formulas excluded by the USP.

Import Drugs Act of 1848

The first federal law regulating drug purity in the United States, granting US Customs the authority to inspect and reject adulterated or contaminated drug imports using USP standards.

Pure Food and Drug Act of 1906

Federal legislation prompted by Upton Sinclair's 'The Jungle' that prohibited interstate commerce of adulterated or misbranded food and drugs and required disclosure of active ingredients.

Adulteration

A legal condition under the 1906 Act defining a drug product that is prepared in unsanitary conditions, contaminated, or divergent in strength, quality, or purity from official compendial standards.

Misbranding

A legal condition defining a product whose labeling is false, misleading, or omitting mandatory statutory content and warnings.

Sherley Amendment of 1912

A federal amendment to the 1906 Pure Food and Drug Act that prohibited false and fraudulent claims of therapeutic efficacy on drug labeling.

Sulfanilamide Disaster of 1937

A public health tragedy involving the S.E. Massengill Company in which 107 people died after taking an untested pediatric formulation of sulfanilamide dissolved in diethylene glycol.

Federal Food, Drug, and Cosmetic (FD&C) Act of 1938

Comprehensive federal law enacted in response to the sulfanilamide tragedy that required all new drugs to be proven safe through an approved NDA before marketing and gave the FDA factory inspection powers.

Wheeler-Lea Act of 1938

Federal legislation granting the Federal Trade Commission (FTC) authority to oversee and regulate the advertising of over-the-counter (non-prescription) drugs.

Durham-Humphrey Amendment of 1951

An amendment to the FD&C Act that formally established two statutory classes of medications: non-prescription over-the-counter (OTC) drugs and prescription ('Legend' / Rx-only) drugs.

Kefauver-Harris Amendments of 1962

Federal amendments enacted following the European thalidomide tragedy requiring drug sponsors to prove both safety and efficacy, implement IND protocols prior to human trials, and adhere to cGMPs.

Phocomelia

A severe congenital birth defect characterized by missing or severely stunted, seal-like limbs, observed in approximately 10,000 European infants exposed in utero to thalidomide.

Drug Efficacy Study Implementation (DESI)

An FDA program begun in 1967 contracting external academic experts to retroactively review the efficacy of all approved drugs marketed between 1938 and 1962.

Orange Book

The common name for the FDA publication 'Approved Drug Products with Therapeutic Equivalence Evaluations', which lists approved drug products, patent expirations, and therapeutic equivalence ratings for generic substitutions.

Drug Quality and Security Act of 2013

Federal legislation enacted following the 2012 New England Compounding Center (NECC) contaminated methylprednisolone fungal meningitis outbreak, strengthening FDA authority to regulate and monitor large-scale drug compounding pharmacies.